Sanctuary Advisors LLC Raises Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Sanctuary Advisors LLC boosted its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 78.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,389 shares of the biotechnology company’s stock after buying an additional 20,818 shares during the quarter. Sanctuary Advisors LLC’s holdings in BioCryst Pharmaceuticals were worth $360,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Signaturefd LLC lifted its position in BioCryst Pharmaceuticals by 560.5% in the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 5,599 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,322 shares during the last quarter. nVerses Capital LLC bought a new stake in BioCryst Pharmaceuticals in the second quarter valued at approximately $63,000. Quantinno Capital Management LP bought a new stake in BioCryst Pharmaceuticals in the third quarter valued at approximately $82,000. Finally, DRW Securities LLC bought a new position in shares of BioCryst Pharmaceuticals during the second quarter valued at approximately $74,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on BCRX. Barclays upped their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. Needham & Company LLC restated a “buy” rating and set a $14.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.60.

BioCryst Pharmaceuticals Trading Down 0.1 %

NASDAQ BCRX opened at $7.71 on Friday. BioCryst Pharmaceuticals, Inc. has a 12 month low of $4.03 and a 12 month high of $8.88. The stock has a market cap of $1.60 billion, a P/E ratio of -12.64 and a beta of 1.79. The stock’s fifty day moving average price is $7.64 and its 200-day moving average price is $7.45.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The business had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. BioCryst Pharmaceuticals’s quarterly revenue was up 35.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.19) earnings per share. As a group, analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.